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Background: China is experiencing increasing burden of acute myocardial infarction (AMI) in the face of limited
medical resources. Hospital length of stay (LOS) is an important indicator of resource utilization.
Methods: We used data from the Retrospective AMI Study within the China Patient-centered Evaluative Assessment
of Cardiac Events, a nationally representative sample of patients hospitalized for AMI during 2001, 2006, and 2011.
Hospital-level variation in risk-standardized LOS (RS-LOS) for AMI, accounting for differences in case mix and year,
was examined with two-level generalized linear mixed models. A generalized estimating equation model was used
to evaluate hospital characteristics associated with LOS. Absolute differences in RS-LOS and 95% confidence
intervals were reported.
Results: The weighted median and mean LOS were 13 and 14.6 days, respectively, in 2001 (n = 1,901), 11 and
12.6 days in 2006 (n = 3,553), and 11 and 11.9 days in 2011 (n = 7,252). There was substantial hospital level
variation in RS-LOS across the 160 hospitals, ranging from 9.2 to 18.1 days. Hospitals in the Central regions had on
average 1.6 days (p = 0.02) shorter RS-LOS than those in the Eastern regions. All other hospital characteristics
relating to capacity for AMI treatment were not associated with LOS.
Conclusions: Despite a marked decline over the past decade, the mean LOS for AMI in China in 2011 remained
long compared with international standards. Inter-hospital variation is substantial even after adjusting for case mix.
Further improvement of AMI care in Chinese hospitals is critical to further shorten LOS and reduce unnecessary
hospital variation.
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China, like many other low- and middle-income coun-
tries, is challenged to provide care for a large and grow-
ing population with cardiovascular conditions [1]. It is
estimated that 16 million people will suffer acute myo-
cardial infarction (AMI) in 2020 and 23 million in 2030
in China [2]. However, the country has limited medical
structural resources to dedicate to the care of this in-
creasingly common condition. The availability of hos-
pital beds is limited; but, paradoxically, studies suggest
that hospital length of stay (LOS) is longer in China* Correspondence: jiangl@fwoxford.org
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unless otherwise stated.compared with most other countries [3-6], which further
strains resource availability. Prolonged hospitalization can
expose patients to harm, including risks for hospital-
acquired infections, deep vein thrombosis, pulmonary
embolism, and medical errors [7,8]. Moreover, days in
hospital that do not contribute to meaningful improve-
ments in patients’ conditions represent wasteful health
care spending [8-10].
AMI is a particularly suitable condition to study hos-
pital LOS in China. It is a common condition for which
people seek acute care in a wide spectrum of hospitals.
Furthermore, standardized care strategies for AMI are
relatively well-established, and consistent by national
[11,12] and international [13-16] guidelines. There is
also an extensive body of literature demonstrating that
shorter LOS for patients with AMI is not associated withis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mortality [17-20]. Some studies have even shown that
discharge within 72 hours for low-risk and uncompli-
cated patients with AMI can be safe [21-24]. To this
end, several risk-stratification strategies have been sug-
gested to triage patients into different levels of readiness
for discharge [8].
Despite the importance of this issue, relatively little is
known about the patterns of hospital LOS for patients
with AMI across China, with evidence mainly from sin-
gle or very selective tertiary hospitals in urban settings
[5,6]. Accordingly, we examined LOS for AMI in a na-
tionally representative sample of patients hospitalized
for AMI during 2001, 2006, and 2011, which is derived
from the China Patient-centered Evaluative Assessment
of Cardiac Events (PEACE)-Retrospective AMI Study.
We specifically sought to examine the variation in LOS
across hospitals and over time in China and to identify
hospital characteristics that are associated with shorter
LOS, employing methods specifically developed for pro-
filing hospitals.
Methods
Design overview of the China PEACE-retrospective
AMI study
The design of the China PEACE-Retrospective AMI
Study has been published previously [25,26]. In brief, a
nationally representative sample of AMI hospitalizations
was obtained following a two-stage sampling design:
First, we identified hospitals using a simple random sam-
pling procedure within each of the 5 study strata:
Eastern-rural, Central-rural, Western-rural, Eastern-urban,
and Central/Western-urban regions, since hospital volumes
and clinical capacities differ between urban and rural areas
as well as among the three official economic-geographic re-
gions (Eastern, Central, and Western) of Mainland China.
We considered Central and Western urban regions to-
gether given their similar per capita income and health ser-
vices capacity. In the 3 rural strata, the sampling framework
consisted of the central hospital in each of the predefined
rural regions (2010 central hospitals in 2010 rural regions).
In the 2 urban strata, the sampling framework consisted of
the highest-level hospitals in each of the predefined urban
regions (833 hospitals in 287 urban regions). Since the
majority of hospitals in China are publicly owned and ad-
ministered, hospital closure is rare. We selected represen-
tative hospitals from 2011 to reflect current practices and
traced this cohort of hospitals backward to 2006 and 2001
to describe temporal trends. Second, we drew hospitaliza-
tions from the selected hospitals based on the local
hospital database for patients with a definite discharge
diagnosis of AMI in each year using random sampling
procedures. Patients with AMI were identified using Inter-
national Classification of Diseases - Clinical Modificationcodes, including versions 9 (410.xx) and 10 (I21.xx), when
available or through principal discharge diagnosis terms.
Information on the patient characteristics, in-hospital
treatments, and outcomes were extracted from the med-
ical records. Hospital characteristics were derived from a
standardized survey to all the selected hospitals, as well as
information from medical records.
The central ethics committee at the China National
Center for Cardiovascular Diseases approved the China
PEACE-Retrospective AMI Study. All collaborating
hospitals accepted the central ethics approval except for
five hospitals, which obtained local approval. The
Chinese government, who provided financial support
for the study, had no role in the design or conduct of
the study; in the collection, management, analysis, and
interpretation of the data; or in the preparation or ap-
proval of the manuscript. The study is registered at
www.clinicaltrials.gov (NCT01624883).
Study sample
Our study sample included 16,100 patients who had
AMI on presentation to the hospital. We excluded those
who died within hospital, who withdrew treatment by
request of the patient or the family due to deteriorating
clinical condition, who transferred into or out of the
hospital, or who had a coronary artery bypass graft
(CABG) during hospitalization (Figure 1). In a secondary
analysis, we considered only the subgroup of patients with-
out major complications during hospitalization, for whom
an extended LOS maybe particularly unnecessary. Uncom-
plicated patients were defined as those without recurrent
myocardial infarction or angina, cardiogenic shock, cardiac
arrest, new-onset heart failure, atrial fibrillation, ventricular
tachycardia or fibrillation, stroke, bleeding, acute renal fail-
ure, or infection during hospitalization.
Covariates
Patient-level characteristics
Data elements were identified from the front page of the
medical record (i.e. patient’s sociodemographic characteris-
tics and a summary of major events during hospitalization),
admission records (including conditions at presentation,
history of disease, personal lifestyle and reproductive his-
tory, physical examination, and auxiliary examination),
daily records (events during hospitalization), in-hospital
procedure reports (e.g. device placement, coronary angiog-
raphy, percutaneous coronary intervention (PCI), and
CABG), diagnostic examination reports (e.g. imaging, elec-
trocardiography, and lab tests), long-term and short-term
physician orders, and discharge records. Variables were
classified into categories, including sociodemographic and
medical characteristics; diagnostic tests, medications, and
procedures received during hospitalization; and in-hospital
outcomes.
Figure 1 Flow diagram of study population.
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Hospital characteristics included geographic region
(Eastern/Central/Western), hospital level (tertiary/second-
ary), teaching status, annual AMI patient volume, avail-
ability of an independent cardiology department, cardiac
catheterization, and the capacity to conduct biomarkers
testing (creatine kinase, creatine kinase MB fraction, and
troponin).
Outcome
LOS in days was primarily determined by the admission
and discharge dates documented on the front page of
the medical records, and complemented by other sec-
tions of the record when either date was missing, unin-
terpretable, or mis-documented on the front page.
Statistical analysis
Hospitals were divided into tertiles based on the median
LOS across all years. To assess statistical differences and
take into account the clustering of patients within hospi-
tals, patient characteristics were compared across the
tertiles of hospitals using the Chi-square test or ANOVA
for clustered data. We also examined the trends in LOS
over the study period among all patients and in uncompli-
cated patients only. Mann-Kendall trend test was used
based on three time points (2001, 2006, and 2011). When
deriving the patient-level LOS statistics, the weight for each
patient was the inversed sampling fraction of patients from
the hospital multiplied by the inverse sampling fraction of
hospitals from the geographic region for each study year.
Our subsequent analytic cohort further excluded pa-
tients who had LOS lower than the 1st percentile value
(i.e. who were discharged on the same day or overnight)
or greater than the 99th percentile value (>42 days).
LOS was considered a log-normal distribution. In the
overall study sample, two-level generalized linear mixedmodel with patients nested within hospitals was used to
determine the risk-standardized LOS (RS-LOS). The
“risk profile” consisted of factors that may be associated
with the hospitalization LOS, including patient’s sociode-
mographics, cardiac and noncardiac comorbidities, indi-
cators of the severity of AMI, and year. RS-LOS for each
patient was defined as the ratio of predicted to expected
LOS, multiplied by the average LOS of the cohort. The
expected LOS for each patient was estimated by apply-
ing the estimated regression coefficients to the charac-
teristics of the patient and adding the average of the 160
hospital-specific intercepts. The predicted LOS of each
patient was calculated with similar methods but using
individual hospital-specific intercepts instead of the aver-
age value. Therefore, although RS-LOS was technically
calculated for each patient based on the model, it was
really a hospital-specific indicator (i.e. patients within
the same hospital had identical RS-LOS).
Furthermore, we assessed inter-hospital variation in
RS-LOS across the study years, among all hospitals as well
as stratified by secondary and tertiary hospital levels. We
did not adjust for patient in-hospital treatments and com-
plications as they could act as mediators, and adjustment
for these factors may result in underestimates of variation.
Lastly, we examined the association of year-specific hos-
pital RS-LOS with the selected hospital characteristics,
some of which might change over the years for the same
hospital. Year-specific hospital RS-LOS was derived simi-
larly as described above, except it was estimated separately
in patients from each of three study years. We fit a gener-
alized estimating equation (GEE) linear model, weighted
by hospitals’ AMI patient volume for each study year in
the study sample to account for the uncertainty in the esti-
mates of RS-LOS, and took into account the correlations
of different year-specific observations for the same hos-
pital. Absolute differences in RS-LOS and 95% confidence
Table 1 Characteristics of patients in tertiles of hospitals with regard to median length of stay
All hospitals
(n = 12706)
High-tertile
hospitals (n = 4784)
Middle-tertile
hospitals (n = 5105)
Low-tertile
hospitals (n = 2817)
P-value
Length of stay, median (IQR)
2001 13 (8–19) 14 (9–21) 14 (9–18) 11 (7–16) 0.004
2006 11 (7–16) 13 (9–19) 11 (7–15) 8 (5–12) <.0001
2011 11 (7–15) 14 (9–18) 11 (8–14) 9 (6–12) <.0001
Year of admission 0.01
2001 1901 (15.0) 773 (16.2) 834 (16.3) 294 (10.4)
2006 3553 (28.0) 1361 (28.5) 1391 (27.3) 801 (28.4)
2011 7252 (57.1) 2650 (55.4) 2880 (56.4) 1722 (61.1)
Socio-demographics
Age, years
Mean ± std 64.4 ± 12.5 63.8 ± 12.4 64.5 ± 12.7 65.1 ± 12.1 0.2
<55 2905 (22.9) 1176 (24.6) 1172 (23.0) 557 (19.8) 0.07
55-64 3073 (24.2) 1125 (23.5) 1237 (24.2) 711 (25.2)
65-74 3779 (29.7) 1455 (30.4) 1460 (28.6) 864 (30.7)
≥75 2949 (23.2) 1028 (21.5) 1236 (24.2) 685 (24.3)
Female 3779 (29.7) 1385 (29.0) 1574 (30.8) 820 (29.1) 0.4
Place of residence 0.1
Urban 3489 (27.5) 1525 (31.9) 1316 (25.8) 648 (23.0)
Rural 8266 (65.1) 3087 (64.5) 3166 (62.0) 2013 (71.5)
Unrecorded 951 (7.5) 172 (3.6) 623 (12.2) 156 (5.5)
Cardiac risk factors
Current smoking 4406 (34.7) 1836 (38.4) 1659 (32.5) 911 (32.3) 0.03
Hypertension 5743 (45.2) 2252 (47.1) 2323 (45.5) 1168 (41.5) 0.3
Diabetes 2095 (16.5) 805 (16.8) 914 (17.9) 376 (13.4) 0.1
Medical histories
Myocardial infarction 1369 (10.8) 466 (9.7) 639 (12.5) 264 (9.4) 0.008
Percutaneous coronary intervention 248 (2.0) 95 (2.0) 113 (2.2) 40 (1.4) 0.4
CABG 45 (0.4) 21 (0.4) 19 (0.4) 5 (0.2) 0.4
Stroke 1377 (10.8) 517 (10.8) 568 (11.1) 292 (10.4) 0.9
Chronic renal disease 2527 (19.9) 799 (16.7) 1076 (21.1) 652 (23.2) 0.02
Cancer 72 (0.6) 14 (0.5) 21 (0.4) 37 (0.8) 0.1
Presentation features
Symptom onset to admission 0.5
≤6 hours 4838 (38.1) 1891 (39.5) 1925 (37.7) 1022 (36.3)
6-12 hours 1290 (10.2) 477 (10.0) 525 (10.3) 288 (10.2)
12-24 hours 1635 (12.9) 635 (13.3) 626 (12.3) 374 (13.3)
>24 hours 4943 (38.9) 1781 (37.2) 2029 (39.8) 1133 (40.2)
STEMI 10888 (85.7) 4190 (87.6) 4293 (84.1) 2405 (85.4) 0.07
Chest pain 11746 (92.4) 4421 (92.4) 4719 (92.4) 2606 (92.5) 0.9
Cardiogenic shock 475 (3.7) 190 (4.0) 175 (3.4) 110 (3.9) 0.6
Cardiac arrest 105 (0.8) 48 (1.0) 39 (0.8) 18 (0.6) 0.3
Pneumonia 1188 (9.4) 416 (8.7) 486 (9.5) 286 (10.2) 0.7
Exacerbated COPD 203 (1.6) 73 (1.5) 76 (1.5) 54 (1.9) 0.6
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Table 1 Characteristics of patients in tertiles of hospitals with regard to median length of stay (Continued)
Acute stroke 114 (0.9) 41 (0.9) 43 (0.8) 30 (1.1) 0.6
eGFR, ml/min/1.73 m2
Mean ± std 84.6 ± 38.6 88.7 ± 37.4 82.9 ± 37.5 80.5 ± 42.0 0.008
>90 4210 (33.1) 1848 (38.6) 1630 (31.9) 732 (26.0) 0.0006
60-90 4158 (32.7) 1515 (31.7) 1792 (35.1) 851 (30.2)
<60 2389 (18.8) 759 (15.9) 1017 (19.9) 613 (21.8)
Unknown 1949 (15.3) 662 (13.8) 666 (13.1) 621 (22.0)
Systolic blood pressure >180 mmHg
or diastolic blood pressure >110 mmHg
671 (5.3) 227 (4.7) 297 (5.8) 147 (5.2) 0.5
Heart rate > 100 beats/min 1379 (10.9) 493 (10.3) 572 (11.2) 314 (11.2) 0.5
Outliers of outcome
<1st percentile value (i.e. <2 days) 316 (2.5) 102 (2.1) 101 (2.0) 113 (4.0) 0.001
>99th percentile value (i.e. >42 days) 121 (1.0) 69 (1.4) 44 (0.9) 8 (0.3) < .0001
IQR: interquartile range; std: standard deviation; CABG: coronary artery bypass graft; STEMI: ST-segment elevation myocardial infarction; COPD: chronic obstructive
pulmonary disease; eGFR: estimated glomerular filtration rate.
Numbers in the second to the fifth columns represent count (percentage), unless otherwise specified.
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tic, adjusting for temporal (i.e. year) effect.
All comparisons were 2-sided, with a p-value less than
0.05 considered statistically significant. Statistical analysis
was performed using the SAS software (version 9.3, SAS
Institute, Cary, NC).
Results
Characteristics of patients in tertiles of hospitals with
regard to crude median LOS
The median and interquartile range (IQR) of LOS was
13 (8–19) days in 2001, 11 (7–16) days in 2006, and 11
(7–15) days in 2011 (Table 1); the rankings of the aver-
age LOS of the three tertiles of hospitals were consistent
throughout the three study years. Compared with hospi-
tals in the low tertile of median LOS, high-tertile hospi-
tals contributed more patients to our study sample in
2001 (16.2% vs. 10.4%) and fewer in 2011 (55.4% vs.
61.1%). With respect to patient characteristics by tertiles
of hospitals, high-tertile hospitals had a greater proportion
of current smokers (38.4%) and a lower proportion of pa-
tients with chronic renal disease (16.7%); middle-tertile
hospitals had a greater proportion of patients with a his-
tory of MI (12.5%); and low-tertile hospitals had fewer pa-
tients with estimated glomerular filtration rate > 90 ml/
(min*1.73 m2) (26.0%). Other patient characteristics were
not statistically different across the three tertiles of hospi-
tals. Of note, with regard to the distribution of outliers in
LOS, low-tertile hospitals had more patients who had LOS
of 0 or 1 day (4.0%), while high-tertile hospitals had more
patients who had LOS of >42 days (1.4%).
As Table 2 shows, 8.2% of the patients in high-tertile
hospitals received no biomarker testing in contrast to
17.0% in low-tertile hospitals. Percentages of medication
use, reperfusion therapies, and overall cardiac proceduresduring the hospitalization were similar between patients in
hospitals from the three tertiles. In-hospital outcomes were
also similar (Table 3), except for in-hospital infection –
12.6% of the patients had infections acquired during
hospitalization in high-tertile hospitals, whereas the pro-
portions were 10.8% and 8.7% for middle- and low-tertile
hospitals, respectively.
Year trend of Hospital LOS for AMI
Compared with 2001, LOS for patients with AMI de-
creased in 2006 and 2011 (p for trend <0.001) (Figure 2).
After weighting, among the 1,901 patients from 2001 the
mean LOS was 14.6 days. The corresponding LOS for
2006 (n = 3,553) and 2011 (n = 7,252) were 12.6 and
11.9 days, respectively. Among the 8,049 uncomplicated
patients, the weighted mean LOS was 13.4 days for the
1,196 patients from 2001, 11.2 days for the 2,243 patients
from 2006, and 10.8 days for the 4,610 patients from 2011.
In the multivariable risk-standardization model, after
adjusting for other patient characteristics, study year was
significantly associated with LOS for AMI. Compared with
a patient with the same underlying risk in 2011, a patient
in 2001 had a 25% longer LOS (ratio, 1.25; 95% CI, 1.22-
1.29) and a patient in 2006 had an 8% longer LOS (ratio:
1.08; 95% CI, 1.06-1.10). Further information about the
model coefficients and the residual plot of the risk-
standardization model are provided in the Additional file 1.
Variations in risk-standardized LOS across Hospitals
Overall mean hospital RS-LOS was 12.5 (s.d. 1.8 days).
Among all 160 hospitals, there was a substantial vari-
ation in hospital RS-LOS, ranging from 9.2 to 18.1 days
(Figure 3). The patterns of variations were similar between
secondary and tertiary hospitals. Among 95 secondary
hospitals, the mean hospital RS-LOS was 12.0 days,
Table 2 In-hospital diagnostic tests, treatments, and procedures received by patients in tertiles of hospitals with
regard to median length of stay
All hospitals
(n = 12706)
High-tertile hospitals
(n = 4784)
Middle-tertile
hospitals (n = 5105)
Low-tertile
hospitals (n = 2817)
P-value
Diagnostic tests
Echocardiogram 6994 (55.0) 2765 (57.8) 2803 (54.9) 1426 (50.6) 0.6
Ejection fraction
Available 6436 (50.7) 2497 (52.2) 2586 (50.7) 1353 (48.0) 0.8
Mean ± std 54.0 ± 11.8 54.6 ± 11.8 53.9 ± 11.6 53.3 ± 12.3 0.5
Biomarkers 0.04
None 1338 (10.5) 393 (8.2) 466 (9.1) 479 (17.0)
CK only 855 (6.7) 263 (5.5) 399 (7.8) 193 (6.9)
CK-MB only 4685 (36.9) 2094 (43.8) 1650 (32.3) 941 (33.4)
Troponin only 395 (3.1) 112 (2.3) 231 (4.5) 52 (1.9)
CK-MB + Troponin 5433 (42.8) 1922 (40.2) 2359 (46.2) 1152 (40.9)
Medications within 24 hours of admission
Aspirin 11209 (88.2) 4191 (87.6) 4591 (89.9) 2427 (86.2) 0.2
Clopidogrel 7418 (58.4) 2739 (57.3) 3104 (60.8) 1575 (55.9) 0.7
GP IIb/IIIa inhibitors 877 (6.9) 306 (6.4) 392 (7.7) 179 (6.4) 0.8
Unfractionated heparin 9753 (76.8) 3740 (78.2) 3840 (75.2) 2173 (77.1) 0.6
Low-molecular-weight heparin 6953 (54.7) 2692 (56.3) 2742 (53.7) 1519 (53.9) 0.8
Beta-blockers 6328 (49.8) 2346 (49.0) 2657 (52.1) 1325 (47.0) 0.4
Nitrates 10677 (84.0) 3989 (83.4) 4325 (84.7) 2363 (83.9) 0.9
Traditional Chinese medicines 7251 (57.1) 2736 (57.2) 2680 (52.5) 1835 (65.1) 0.3
Medications during the hospitalization
Calcium channel blockers 2206 (17.4) 838 (17.5) 893 (17.5) 475 (16.9) 0.9
ACEIs or ARBs 8345 (65.7) 3226 (67.4) 3311 (64.9) 1808 (64.2) 0.7
Any Statins 9833 (77.4) 3683 (77.0) 4058 (79.5) 2092 (74.3) 0.5
Traditional Chinese medicines 8605 (67.7) 3314 (69.3) 3210 (62.9) 2081 (73.9) 0.4
Reperfusion therapies among STEMI
Primary PCI 1307 (12.0) 506 (12.1) 606 (14.1) 195 (8.1) 0.5
Fibrinolytic therapy 2637 (24.2) 1108 (26.4) 976 (22.7) 553 (23.0) 0.4
Cardiac procedures
Catheterization 3483 (27.4) 1357 (28.4) 1457 (28.5) 669 (23.8) 0.8
PCI 3013 (23.7) 1165 (24.4) 1284 (25.2) 564 (20.0) 0.7
CK: creatine kinase; CK-MB: creatine kinase MB fraction; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; STEMI: ST-segment
elevation myocardial infarction; PCI: Percutaneous coronary intervention.
Numbers in the second to the fifth columns represent count (percentage), unless otherwise specified.
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(see Additional file 2 for the graphic pattern of vari-
ation). Among 65 tertiary hospitals, the mean hospital
RS-LOS was 12.8 days, with a s.d. of 1.7 days and a
range of 9.5 to 17.8 days (see Additional file 3 for the
graphic pattern of variation).
Hospital characteristics associated with risk-standardized
LOS
After adjusting the standard errors of estimates using
GEE, geographic region was the only factor independentlysignificantly associated with hospital RS-LOS (Table 4).
Compared with hospitals in the Eastern region, Central-
region hospitals on average had 1.6 days (p = 0.02) shorter
RS-LOS. All other hospital characteristics relating to cap-
acity for AMI treatment were not significantly associated
with LOS.
Discussion
In this study, we found that the average LOS for patients
with AMI in China decreased by 3 days between 2001
and 2011. However, it remained considerably long, with
Table 3 In-hospital outcomes of patients in tertiles of hospitals with regard to median length of stay
All hospitals
(n = 12706)
High-tertile
hospitals (n = 4784)
Middle-tertile
hospitals (n = 5105)
Low-tertile
hospitals (n = 2817)
P-value
Recurrent myocardial infarction 67 (0.5) 25 (0.5) 25 (0.5) 17 (0.6) 0.8
Cardiac arrest 124 (1.0) 55 (1.2) 47 (0.9) 22 (0.8) 0.3
Cardiogenic shock 154 (1.2) 63 (1.3) 60 (1.2) 31 (1.1) 0.7
New-onset heart failure 1656 (13.0) 612 (12.8) 688 (13.5) 356 (12.6) 0.9
Recurrent angina 2120 (16.7) 883 (18.5) 702 (13.8) 535 (19.0) 0.08
Atrial fibrillation 310 (2.4) 127 (2.7) 104 (2.0) 79 (2.8) 0.2
Stroke 63 (0.5) 29 (0.6) 22 (0.4) 12 (0.4) 0.4
Bleeding 769 (6.1) 321 (6.7) 314 (6.2) 134 (4.8) 0.2
Acute renal failure 66 (0.5) 26 (0.5) 31 (0.6) 9 (0.3) 0.4
Ventricular tachycardia or fibrillation 426 (3.4) 175 (3.7) 163 (3.2) 88 (3.1) 0.7
Infection 1397 (11.0) 601 (12.6) 551 (10.8) 245 (8.7) 0.04
Numbers in the second to the fifth columns represent count (percentage), unless otherwise specified.
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major complications, the mean LOS was 11 days. Varia-
tions in LOS across both secondary and tertiary hospi-
tals were significant and persisted after adjusting for
case mix. Regional differences were also observed, as
hospitals from the Central region had about a day and a
half shorter LOS for patients with AMI compared with
Eastern region hospitals. Finally, hospital capacity for
AMI treatment was not associated with LOS.Figure 2 Year-trend Whisker plot of length of stay. Diamond inside the
box: interquartile range (IQR); bottom and top edges of the whiskers: 1.5*IQThe LOS for AMI in China is longer than that in clin-
ical practice of Western countries. Existing literature
suggests that the average LOS for AMI patients ranges
from three to eight days for most developed countries
during our study period [3,17,19,27,28], with an excep-
tion of Japan, where LOS is as long as 17–20 days [29].
Contemporary trends and hospital variation in LOS for
patients with AMI in China have not been previously re-
ported. Our study shows that LOS for uncomplicatedbox: mean; line inside the box: median; bottom and top edges of the
R; points beyond the whiskers: outliers.
Figure 3 Risk-standardized length of stay across all hospitals.
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http://www.biomedcentral.com/1471-2261/15/9patients with AMI in China is still considerably long,
suggesting that the duration of the hospital stay does not
reflect patient needs. Smith et al. [23] reported that
many doctors across different countries are still conser-
vative in terms of discharge, especially facing patients
with AMI who are usually elderly and with many comor-
bidities, which is likely the case in China as well. In
addition, the post-hospitalization care for AMI patients,
such as cardiac rehabilitation and clinician’s follow-up
check-ups, were not as common in China as in the
Western countries [30-32]. Considering that timely ad-
mission after symptom onset is still problematic for pa-
tients with AMI [26], and patients post-AMI likewise,
the potential consequence of developing complications
outside hospital might be even more deleterious for pa-
tients with AMI in China. Moreover, Chinese doctors
tend to be conservative to avoid potential challenges,
legal action, or even threats from patients or their fam-
ilies, who might get angry if they are sent home and
have a complication [33,34].
The structure of healthcare financing may also partially
explain why LOS is longer in China than in other coun-
tries [35]. For example, the U.S. Medicare prospective pay-
ment system and diagnosis related group (DRG)-based
payment system for hospitalizations gives predetermined
reimbursements to hospitals independently of LOS, pro-
viding financial incentives for early discharge. China, on
the other hand, largely uses a fee-for-service mechanism[36], which may incentivize those providers or hospitals
where hospital beds outnumber patient demand to pro-
long patient’s hospitalization and generate more revenue.
In addition, in many health insurance schemes in China,
the amount of reimbursement to patients is higher for in-
patient service than in the outpatient setting [37,38].
Therefore, some patients may opt to stay in hospital lon-
ger in order to have other comorbid conditions checked
or treated, and have more medications prescribed during
hospitalization or at discharge.
The declining trend of LOS for AMI in our study is
consistent with what has been observed in many other
countries over time [18,19,39]. There are various reasons
for this observation. For example, in the U.S., the DRG-
based payment system provides major incentives, in
addition to the increasing adoption of hospitalist pro-
grams that help to decrease LOS [40]. In China, it could
be due to increases in biomarker testing that may have
led to faster diagnosis and treatment, increasing use of
some guideline-recommended therapies as we saw in the
China PEACE-Retrospective AMI Study data [26], or
system and organizational strategy improvements [41].
We found substantial inter-hospital variations in LOS
for AMI hospitalization in China, with only a small
amount of heterogeneity in patient characteristics and risk
profiles. This has been similarly observed in Western coun-
tries, where healthcare practice is considered more stan-
dardized [42-45]. Moreover, the characteristics indicating a
Table 4 Hospital characteristics associated with year-specific risk-standardized length of stay
Hospital characteristics N (%) Difference in risk-standardized length of stay
and 95% confidence intervals (in days)
P-value
2001 2006 2011
(n = 130) (n = 152) (n = 158)
Geographic region
Eastern 55 (42.3) 60 (39.5) 63 (39.9) 0 (ref)
Central 41 (31.5) 48 (31.6) 48 (30.4) −1.6 (−2.9, −0.2) 0.02
Western 34 (26.2) 44 (29.0) 47 (29.8) 0.3 (−1.1, 1.6) 0.7
Tertiary (vs. secondary) 56 (43.1) 64 (42.1) 65 (41.1) 0.5 (−0.7, 1.7) 0.4
Affiliated/teaching status
Neither affiliated nor teaching 37 (28.5) 42 (27.6) 42 (26.6) 0 (ref)
Teaching but not affiliated 48 (36.9) 53 (34.9) 54 (34.2) 0.2 (−1.0, 1.3) 0.8
Both teaching and affiliated 45 (34.6) 57 (37.5) 62 (39.2) −0.4 (−2.1, 1.2) 0.6
Annual AMI patients volume
≤10 58 (44.6) 39 (25.7) 17 (10.8) 0 (ref)
11-30 37 (28.5) 43 (28.3) 29 (18.4) 0.1 (−0.9, 1.2) 0.8
31-80 25 (19.2) 35 (23.0) 52 (32.9) 0.6 (−0.7, 1.8) 0.4
>80 10 (7.7) 35 (23.0) 60 (38.0) 0.8 (−0.6, 2.2) 0.3
Cardiac catheterization (vs. not) 33 (25.4) 58 (38.2) 74 (46.8) 0 (−0.5, 0.5) 0.9
Independent cardiology department (vs. not) 28 (21.5) 58 (38.2) 78 (49.4) −0.3 (−0.7, 0.2) 0.2
Capacity to test biomarkers
None 24 (18.5) 11 (7.2) 2 (1.3) 0 (ref)
CK only 29 (22.3) 9 (5.9) 2 (1.3) 0.1 (−1.1, 1.3) 0.9
CK-MB 44 (33.9) 44 (29.0) 27 (17.1) 0.2 (−0.8, 1.2) 0.7
Troponin 33 (25.4) 88 (57.9) 127 (80.4) 0.4 (−0.6, 1.5) 0.4
CK: creatine kinase; CK-MB: creatine kinase MB fraction.
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http://www.biomedcentral.com/1471-2261/15/9hospital’s capacity for AMI treatment were not found to be
associated with hospital RS-LOS either, which was also ob-
served in another study [44]. This suggests that a hospital’s
organizational or operational strategies – or conventional
institutional practices – may play a substantial role in de-
termining how long a patient with AMI stays in the hos-
pital. Of note, the exclusion rate based on the criteria in
Figure 1 was similar in different geographic regions or hos-
pitals with relatively long vs. short RS-LOS, so differential
selection of patients would not explain the variations by re-
gion or hospital.
In the era of medical resource constraint in China, it is
important to explore opportunities where greater effi-
ciency could be recognized. Clinical pathways may be one
solution, which are management plans that standardize
the sequence and timing of the care process to achieve op-
timal treatment effects for patients and efficiency for hos-
pitals. They are designed based on clinical guidelines and
the best evidence from health services research [5]. Since
2009, the Chinese National Health and Family Planning
Commission has designed clinical pathways for 331diseases under 22 disciplines, including AMI, and started
implementing them on a trial basis in public hospitals
[35]. The goal is to improve healthcare quality and effi-
ciency, and potentially reduce variations in care. Previous
research in China and other countries has shown that clin-
ical pathways could improve treatment outcomes and, in
particular, reduce LOS for a variety of major health condi-
tions [5,46-48]. Therefore, it might be helpful to strengthen
and expand the implementation of clinical pathways to
more hospitals outside of a trial basis in China to improve
LOS for patients with AMI. On a larger scale, clinical path-
ways management is part of an attempt to implement
DRG-based payment systems in China to reduce medical
costs [49], with the expectation, in part, of reducing un-
necessarily extended length of stay, as was seen in coun-
tries like the U.S. and Germany after the introduction of
these systems [50,51]. In China, DRG payment has been
established on a trial basis in selected hospitals and dis-
eases since 2004 [52]. However, over the years, it has made
little progress and still has many barriers in terms of imple-
mentation in general practice [52].
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http://www.biomedcentral.com/1471-2261/15/9Although prolonged LOS is associated with increased
consumption of healthcare resources that may or may
not translate into better health outcomes, a recent large
study conducted among U.S. Veterans Affairs hospitals
suggested that hospitals that tend to discharge patients
sooner than expected also have modestly higher re-
admission rates [20]. Furthermore, a prior study also
showed that country-level median LOS was associated
with a 14% reduction in the odds of readmission for
each additional day in hospital [3]. These highlight that
future activities to rationalize hospitalization LOS in
China should be designed and implemented appropri-
ately, avoiding improving hospital patient flow at the
cost of suboptimal patient outcomes.
Our study has several strengths. First, to our know-
ledge, this is the first study in China that thoroughly ex-
amined LOS for AMI using a nationally representative
sample of patients from both secondary and tertiary hos-
pitals. Data from the three study years also enabled us to
study the trend in LOS for AMI over the past decade.
Second, the China-PEACE study implemented rigorous
data quality monitoring with methods commonly used
for clinical trials to improve not only the completeness
but also the accuracy of data extraction [25]. Most pa-
tient characteristics that have been previously suggested
to be associated with LOS for AMI are captured in our
data and included in the risk standardization model
[44,53-55]. However, we also acknowledge that the qual-
ity of medical chart documentation might be uneven, as
there is much heterogeneity across hospitals in China
and could be influenced by physician practice. Finally,
the collaboration with the Chinese government on
China-PEACE will lead to easier translation of our find-
ings into policies and programs to reduce hospital LOS
for AMI. On the other hand, the study was not without
limitations. We did not have information on certain hos-
pital characteristics that may be very relevant to our
analyses, such as whether an AMI clinical pathway was
established in the hospital in a given year. Also, the
cross-sectional nature of the current study prevented us
from examining the association between LOS and pa-
tient prognoses, such as readmission or post-discharge
life quality, on patient or hospital level.Conclusions
Although decreasing in the past decade, hospital LOS
for patients with AMI in China is still long relative to
most countries in the world. There is much inter-hospital
variation in LOS for AMI hospitalizations. In the context
of the growing number of AMI hospitalizations in China,
it is critical to rationally shorten LOS, reduce variations in
practice among hospitals, and ultimately improve the effi-
ciency of Chinese medical resource utilization.Additional files
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